HQ Capital

HQ Capital, established in 2015, is a global alternative investment manager headquartered in Germany. With over $12 billion in assets under management, the firm specializes in private equity and real estate. HQ Capital offers tailored investment solutions, leveraging its global network and local teams' expertise to meet clients' specific needs. The company's investment approach combines entrepreneurial spirit with a long-term focus on generating attractive returns. HQ Capital was formed by merging independent managers Auda, Real Estate Capital Partners, and Equita, bringing together over 25 years of experience in global private equity and U.S. real estate, as well as majority stakes acquisitions in small- and mid-sized European companies. The firm aligns its interests with clients by having its senior team and anchor investor, the Harald Quandt family, make significant financial contributions.

Jacob Chiu

Managing Director, Head of Asian Investments and Member of the Executive Committee

Amit Dabas

Director

Michael Hu

Managing Director and Executive Committee Member

Patrick Knoefler

Managing Director and Executive Committee Member

Britta Lindhorst

Managing Director, Head of European Investments and Global Head of ESG / Impact

Oliver Schlümer

Director

Kenneth Ward-Smith

Managing Director

Stephen Wesson

Managing Director, General Partner, Executive Committee Member and Investment Committee Member

Benjamin Wilson

Managing Director and Executive Committee Member

Lucian Wu

Managing Director

Lily Young

Associate

1 past transactions

Interlace Medical

Series C in 2009
Interlace Medical, Inc. specializes in designing and developing medical devices tailored for interventional gynecologists. The company's primary focus is on creating innovative solutions for office-based procedures that address gynecological diseases and conditions that have historically necessitated surgical intervention in operating rooms. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its advancements, Interlace Medical aims to enhance the efficiency and effectiveness of gynecological treatments, thereby improving patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.